Latest Icu Medical (ICUI) Headlines
Blood and Cardiac Monitoring Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2019
M2 - Thu Mar 13, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vzjflp/blood_and_cardiac) has announced the addition of the "Blood and Cardiac Monitoring Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2019" report to their offering. According to the report the global blood and cardiac monitoring devices market was worth $13.6 billion in 2012 and is expected to reach $20.5 billion in 2019, growing at a CAGR of 6.0% from 2013 to 2019. The market for blood monitoring devices is segmented into blood pressure monitors, blood glucose monitors, blood gas analyzers and blood cholesterol monitors. In 2012, the market for blood glucose monitors accounted for the largest share by revenue of the total market at more than 70%. This is attributed mainly to the consistent technological up-gradations in product design followed by the alarming rise in diabetic population and sedentary lifestyles. However, the blood pressure monitors market is expected to record the highest growth during the forecast period owing to the rising prevalence and incidence rate of hypertension and increased awareness about regular monitoring of blood pressure among people. Also, due to integration of tele-medicine, patients themselves rely on self-monitoring of blood pressure at home. The market for cardiac monitoring devices has been segmented into various device types including electrocardiogram, holter monitors, event monitors, cardiac output monitors, and others (wrist rate monitors, strapped rate monitors, etc.). Of these, the market for electrocardiograms accounted for the largest share by revenue in 2012, at around 45%. Geographically, the market has been segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). North America led the global market for both blood and cardiac monitoring devices in 2012, in terms of revenue share. With innovations in blood monitoring making the testing much less invasive for the geriatric population and other cardiac patients, revenue for the North American market is set to skyrocket. Physicians in the region are increasingly demanding to work with the newer, less invasive or noninvasive systems, which will help in rapid growth of the minimally and non-invasive blood and cardiac monitoring markets. The fastest growth in this market will be observed in the Asia-Pacific region during the forecast period. Sedentary lifestyles and the resultant rise in the prevalence of chronic illnesses, increase in the per capita income and healthcare expenditures, improvement in healthcare infrastructure and a large pool of geriatric population are the key factors fuelling market growth in the region. The market for cardiac monitors is highly oligopolistic in nature, with the top two players accounting for the majority of the market share in 2012. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics: Global Blood and Cardiac Monitoring Devices Market - Products Market Size & Forecast - Global Blood and Cardiac Monitoring Devices Market - Geography Market Size & Forecast - Global Blood and Cardiac Monitoring Devices Market - Key Players Analysis: Global Blood and Cardiac Monitoring Devices Market, 2012 (%) - Company Profiles Companies Mentioned - Dragerwerk AG & Co. - Edwards Lifesciences - GE Healthcare - ICU Medical - LiDCO - Medtronic - Mortara - Nihon Kohden - Omron - Philips Healthcare - Roche - Schiller - Spacelabs Healthcare - Welch Allyn For more information visit http://www.researchandmarkets.com/research/vz...nd_cardiac About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
ICU Medical, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 03, 3:10PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, announced today that Scott Lamb, the Company's Chief Financial Officer, will be presenting at the 26 Annual ROTH Conference to be held on March 9-12, 2014 at the Ritz-Carlton Hotel in Laguna Niguel, CA.
Weakness Seen in ICU Medical (ICUI) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:59AM CST
ICU Medical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
ICU Medical, Inc. Awards Employment Inducement Grants to CEO
GlobeNewswire - Wed Feb 26, 12:20PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, awarded inducement grants to Vivek Jain, Chief Executive Officer.
ICU Medical (ICUI) Crumbles: Stock Falls by 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:42AM CST
ICU Medical saw a big move last session, as the company’s shares fell by nearly 7% on the day
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Wed Feb 12, 3:12PM CST
Company Appoints Mr. Vivek Jain as New Chief Executive Officer and Chairman
ICU Medical, Inc. Names Vivek Jain as New Chief Executive Officer and Chairman
GlobeNewswire - Wed Feb 12, 3:07PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, announced today the appointment of Vivek Jain as chairman and chief executive officer effective February 13, 2014, concluding a transition process that began when Dr. George Lopez announced his decision to retire as CEO in the fall of 2013. Steve Riggs, the Company's current acting Chief Executive Officer, will immediately resume his previous responsibilities as vice president of Operations.
ICE Canola Down As StatsCan Confirms Large Stocks
Phil Franz-Warkentin, Commodity News Service Canada - Commodity News Service Canada, Inc. - Tue Feb 04, 9:01AM CST
ICE Canada canola contracts were posting small losses Tuesday morning in very quiet activity. Confirmation of the burdensome supply situation in Western Canada accounted for some of the weakness.
Commercial Real Estate Investment Up
All Africa Global Media - Wed Jan 22, 4:05AM CST
Global commercial real estate investment volumes in 2013 were up 18 per cent and are expected to exceed $600 billion this year, according to the latest analysis from Jones Lang LaSalle.
Aegerion Pharmaceuticals, Inc. Stockholders Encouraged to Contact Securities Law Firm about Investigation
PR Newswire - Fri Jan 17, 10:19AM CST
Securities lawyers at Deans & Lyons announce an investigation of the board of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Concerned AEGR investors who purchased between April 30, 2013 and January 9, 2014 are encouraged to contact securities attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ICU Medical Inc to participate at the 32nd Annual JP Morgan Healthcare Conference in San Francisco
M2 - Tue Jan 07, 7:17AM CST
ICU Medical Inc (NasdaqGS:ICUI) said on Monday that it will give a presentation at the 32nd Annual JP Morgan Healthcare Conference to be held between 13-16 January 2014 in San Francisco, CA.
ICU Medical, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:10PM CST
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced that Company management will be presenting at the 32 Annual J.P. Morgan Healthcare Conference to be held on January 13-16, 2014, at the Westin St. Francis Hotel in San Francisco, CA.
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Exelixis, Inc. (NASDAQ: EXEL), Cempra, Inc. (NASDAQ: CEMP), Exact Sciences Corporation (NASDAQ: EXAS), and Onconova Therapeutics, Inc. (NASDAQ: ONTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
10-Q: SOURCE GOLD CORP.
Edgar Online - Wed Dec 18, 12:38PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATION
New Clinical Studies Show ICU Medical's ChemoLock(TM) Closed System Transfer Device Prevents Hazardous Drug Surface Contamination and Provides a Completely Dry Disconnect
PR Newswire - Thu Dec 12, 7:00AM CST
ICU Medical, Inc. (NASDAQ: ICUI) today announced that two new studies presented yesterday at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando demonstrated that the company's newly launched ChemoLock(TM) closed system transfer device (CSTD) prevents hazardous drug surface contamination while eliminating leakage and providing a completely dry disconnect.
ICU Medical Launches the ChemoLock(TM) Needlefree Closed System Transfer Device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting
PR Newswire - Mon Dec 09, 7:00AM CST
ICU Medical, Inc. (NASDAQ: ICUI) today announced that will formally launch the ChemoLockTM needlefree closed system transfer device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando December 9-11, 2013. ChemoLock is the first and only needlefree CSTD to receive United States Food and Drug Administration (FDA) 510(k) clearance for pharmacy applications (product code ONB), as well as patient administration applications (product code FPA).
Additions to the Board of Directors, Trial Updates, New Contracts, and Management Changes - Research Report on Charles River Laboratories, Synageva, ICU Medical, ICON, and Hanger
PR Newswire - Fri Dec 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories International, Inc. (NYSE: CRL), Synageva BioPharma Corporation (NASDAQ: GEVA), ICU Medical, Inc. (NASDAQ: ICUI), ICON plc (NASDAQ: ICLR), and Hanger, Inc. (NYSE: HGR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ICU Medical Receives Premier Inc. Contract for the New Diana(TM) Hazardous Drug Compounding System with Barcode Scanning
PR Newswire - Mon Dec 02, 7:00AM CST
ICU Medical Inc. (NASDAQ: ICUI) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the DianaTM hazardous drug compounding system, the world's first user-controlled, automated sterile compounding system for the accurate, safe, and efficient preparation of hazardous drugs. Effective in 2014, this is the first time the Diana system, introduced in the United States in 2012, has been on contract with a group purchasing organization. A new version of the Diana system that incorporates a barcode scanning system will be debuted at the American Society of Hospital Pharmacists (ASHP) midyear clinical meeting in Orlando, FL, December 8-12, 2013.
Blood and Cardiac Monitoring Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2019
M2 - Thu Mar 13, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vzjflp/blood_and_cardiac) has announced the addition of the "Blood and Cardiac Monitoring Devices Market Assessment Report - Global Size, Share, Competitive Landscape, Future Prospects and Forecast from 2013-2019" report to their offering. According to the report the global blood and cardiac monitoring devices market was worth $13.6 billion in 2012 and is expected to reach $20.5 billion in 2019, growing at a CAGR of 6.0% from 2013 to 2019. The market for blood monitoring devices is segmented into blood pressure monitors, blood glucose monitors, blood gas analyzers and blood cholesterol monitors. In 2012, the market for blood glucose monitors accounted for the largest share by revenue of the total market at more than 70%. This is attributed mainly to the consistent technological up-gradations in product design followed by the alarming rise in diabetic population and sedentary lifestyles. However, the blood pressure monitors market is expected to record the highest growth during the forecast period owing to the rising prevalence and incidence rate of hypertension and increased awareness about regular monitoring of blood pressure among people. Also, due to integration of tele-medicine, patients themselves rely on self-monitoring of blood pressure at home. The market for cardiac monitoring devices has been segmented into various device types including electrocardiogram, holter monitors, event monitors, cardiac output monitors, and others (wrist rate monitors, strapped rate monitors, etc.). Of these, the market for electrocardiograms accounted for the largest share by revenue in 2012, at around 45%. Geographically, the market has been segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). North America led the global market for both blood and cardiac monitoring devices in 2012, in terms of revenue share. With innovations in blood monitoring making the testing much less invasive for the geriatric population and other cardiac patients, revenue for the North American market is set to skyrocket. Physicians in the region are increasingly demanding to work with the newer, less invasive or noninvasive systems, which will help in rapid growth of the minimally and non-invasive blood and cardiac monitoring markets. The fastest growth in this market will be observed in the Asia-Pacific region during the forecast period. Sedentary lifestyles and the resultant rise in the prevalence of chronic illnesses, increase in the per capita income and healthcare expenditures, improvement in healthcare infrastructure and a large pool of geriatric population are the key factors fuelling market growth in the region. The market for cardiac monitors is highly oligopolistic in nature, with the top two players accounting for the majority of the market share in 2012. Key Topics Covered - Introduction to the Report - Market Synopsis - Market Dynamics: Global Blood and Cardiac Monitoring Devices Market - Products Market Size & Forecast - Global Blood and Cardiac Monitoring Devices Market - Geography Market Size & Forecast - Global Blood and Cardiac Monitoring Devices Market - Key Players Analysis: Global Blood and Cardiac Monitoring Devices Market, 2012 (%) - Company Profiles Companies Mentioned - Dragerwerk AG & Co. - Edwards Lifesciences - GE Healthcare - ICU Medical - LiDCO - Medtronic - Mortara - Nihon Kohden - Omron - Philips Healthcare - Roche - Schiller - Spacelabs Healthcare - Welch Allyn For more information visit http://www.researchandmarkets.com/research/vz...nd_cardiac About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
ICU Medical, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 03, 3:10PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, announced today that Scott Lamb, the Company's Chief Financial Officer, will be presenting at the 26 Annual ROTH Conference to be held on March 9-12, 2014 at the Ritz-Carlton Hotel in Laguna Niguel, CA.
Weakness Seen in ICU Medical (ICUI) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:59AM CST
ICU Medical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
ICU Medical, Inc. Awards Employment Inducement Grants to CEO
GlobeNewswire - Wed Feb 26, 12:20PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, awarded inducement grants to Vivek Jain, Chief Executive Officer.
ICU Medical (ICUI) Crumbles: Stock Falls by 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:42AM CST
ICU Medical saw a big move last session, as the company’s shares fell by nearly 7% on the day
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Wed Feb 12, 3:12PM CST
Company Appoints Mr. Vivek Jain as New Chief Executive Officer and Chairman
ICU Medical, Inc. Names Vivek Jain as New Chief Executive Officer and Chairman
GlobeNewswire - Wed Feb 12, 3:07PM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in innovative medical devices used in infusion therapy, oncology and critical care applications, announced today the appointment of Vivek Jain as chairman and chief executive officer effective February 13, 2014, concluding a transition process that began when Dr. George Lopez announced his decision to retire as CEO in the fall of 2013. Steve Riggs, the Company's current acting Chief Executive Officer, will immediately resume his previous responsibilities as vice president of Operations.
ICE Canola Down As StatsCan Confirms Large Stocks
Phil Franz-Warkentin, Commodity News Service Canada - Commodity News Service Canada, Inc. - Tue Feb 04, 9:01AM CST
ICE Canada canola contracts were posting small losses Tuesday morning in very quiet activity. Confirmation of the burdensome supply situation in Western Canada accounted for some of the weakness.
Commercial Real Estate Investment Up
All Africa Global Media - Wed Jan 22, 4:05AM CST
Global commercial real estate investment volumes in 2013 were up 18 per cent and are expected to exceed $600 billion this year, according to the latest analysis from Jones Lang LaSalle.
Aegerion Pharmaceuticals, Inc. Stockholders Encouraged to Contact Securities Law Firm about Investigation
PR Newswire - Fri Jan 17, 10:19AM CST
Securities lawyers at Deans & Lyons announce an investigation of the board of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Concerned AEGR investors who purchased between April 30, 2013 and January 9, 2014 are encouraged to contact securities attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ICU Medical Inc to participate at the 32nd Annual JP Morgan Healthcare Conference in San Francisco
M2 - Tue Jan 07, 7:17AM CST
ICU Medical Inc (NasdaqGS:ICUI) said on Monday that it will give a presentation at the 32nd Annual JP Morgan Healthcare Conference to be held between 13-16 January 2014 in San Francisco, CA.
ICU Medical, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:10PM CST
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced that Company management will be presenting at the 32 Annual J.P. Morgan Healthcare Conference to be held on January 13-16, 2014, at the Westin St. Francis Hotel in San Francisco, CA.
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Exelixis, Inc. (NASDAQ: EXEL), Cempra, Inc. (NASDAQ: CEMP), Exact Sciences Corporation (NASDAQ: EXAS), and Onconova Therapeutics, Inc. (NASDAQ: ONTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
10-Q: SOURCE GOLD CORP.
Edgar Online - Wed Dec 18, 12:38PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATION
New Clinical Studies Show ICU Medical's ChemoLock(TM) Closed System Transfer Device Prevents Hazardous Drug Surface Contamination and Provides a Completely Dry Disconnect
PR Newswire - Thu Dec 12, 7:00AM CST
ICU Medical, Inc. (NASDAQ: ICUI) today announced that two new studies presented yesterday at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando demonstrated that the company's newly launched ChemoLock(TM) closed system transfer device (CSTD) prevents hazardous drug surface contamination while eliminating leakage and providing a completely dry disconnect.
ICU Medical Launches the ChemoLock(TM) Needlefree Closed System Transfer Device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting
PR Newswire - Mon Dec 09, 7:00AM CST
ICU Medical, Inc. (NASDAQ: ICUI) today announced that will formally launch the ChemoLockTM needlefree closed system transfer device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando December 9-11, 2013. ChemoLock is the first and only needlefree CSTD to receive United States Food and Drug Administration (FDA) 510(k) clearance for pharmacy applications (product code ONB), as well as patient administration applications (product code FPA).
Additions to the Board of Directors, Trial Updates, New Contracts, and Management Changes - Research Report on Charles River Laboratories, Synageva, ICU Medical, ICON, and Hanger
PR Newswire - Fri Dec 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories International, Inc. (NYSE: CRL), Synageva BioPharma Corporation (NASDAQ: GEVA), ICU Medical, Inc. (NASDAQ: ICUI), ICON plc (NASDAQ: ICLR), and Hanger, Inc. (NYSE: HGR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ICU Medical Receives Premier Inc. Contract for the New Diana(TM) Hazardous Drug Compounding System with Barcode Scanning
PR Newswire - Mon Dec 02, 7:00AM CST
ICU Medical Inc. (NASDAQ: ICUI) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the DianaTM hazardous drug compounding system, the world's first user-controlled, automated sterile compounding system for the accurate, safe, and efficient preparation of hazardous drugs. Effective in 2014, this is the first time the Diana system, introduced in the United States in 2012, has been on contract with a group purchasing organization. A new version of the Diana system that incorporates a barcode scanning system will be debuted at the American Society of Hospital Pharmacists (ASHP) midyear clinical meeting in Orlando, FL, December 8-12, 2013.
